Autres langues Bastide Le Confort Médical

Actions

BLC

FR0000035370

Installations et services en soins de santé

Temps réel Euronext Paris 14:18:38 29/09/2026			Varia. 5j.	Varia. 1 janv.
19,64 ^EUR	-0,30%		-4,89%	-18,17%

28/09	Bastide Le Confort Médical : AlphaValue/Baader Europe favorable sur le dossier	ZM
04/09	Oddo BHF maintient son conseil sur Bastide après la publication du chiffre d'affaires

Autres langues

04/09	Bastide Le Confort Medical : FY sales beat guidance - end of coverage on 1st of October
03/09	Bastide Le Confort Médical Sa Reports Revenue Results for the Year Fourth Quarter and Full Year Ended June 30, 2026
03/09	Bastide Le Confort Médical : Revenue for 2025-2026, excluding the impact of the sale of EXPERF: EUR 526 million, exceeding the target 2025-2026 revenue as reported: EUR 483 million, up 7.6% Recurring operating margin target of around 9% confirmed
31/08	This week's earnings calendar: Broadcom and Dell to keep the AI momentum alive
02/06	France's Groupe Bastide Completes Sale of New Medical Concept Subsidiary
01/06	Bastide Le Confort Médical : Completion of the disposal of New Medical Concept, the holding company of EXPERF Group, to Sapio Group
22/05	Groupe Bastide Strikes Deal to Divest New Medical Concept Unit
21/05	Bastide Le Confort Médical : Groupe Bastide sells New Medical Concept, the holding company of EXPERF group - Erratum
21/05	Bastide Le Confort Médical : Groupe Bastide sells New Medical Concept, the holding company of EXPERF group - Erratum
21/05	Bastide Le Confort Médical : Groupe Bastide sells New Medical Concept, the holding company of EXPERF group
21/05	SAPIO Produzione Idrogeno Ossigeno S.r.l. entered into a definitive agreement to acquire New Medical Concept - Nmc from Bastide Le Confort Médical SA.
15/05	Bastide Le Confort Medical : Guidance confirmed despite transitory regulatory headwinds in Q3
13/05	Bastide Le Confort Médical Sa Reports Revenue Results for the Third Quarter and Nine Month Ended March 31, 2026
13/05	Strong momentum for the first nine months of the financial year: up 7.2% on an organic basis
13/05	Bastide Le Confort Médical : Strong momentum for the first nine months of the financial year: up 7.2% on an organic basis
11/05	Weekly Earnings Calendar
19/03	Bastide Le Confort Medical : Sound H1 results, solid deleveraging, and reaffirmed FY guidance
18/03	Bastide Le Confort Médical : 2025-2026 half-year results
18/03	Bastide Le Confort Médical SA Reports Earnings Results for the Half Year Ended December 31, 2025
18/03	2025-2026 half-year results  Recurring operating margin: 9.0%, in line with the annual target  Operating profit up 12.5%  Operating free cash flow: €24.3 million, a threefold increase in one year  Significant improvement in leverage: 2.77x at December 31, 2025 (vs 3.41x at June 30, 2025) 2025-2026 outlook confirmed
04/03	Bastide Le Confort Medical : 2026.03.04 BLCM - Actions et droits de vote au 28.02.2026
12/02	Bastide Le Confort Médical Sa Reports Revenue Results for the Second Quarter and First-Half Ended December 31, 2025
12/02	Bastide Le Confort Médical Sa Confirms Earnings Guidance for the Fiscal Year 2025-2026
12/02	Organic growth of 8.2% in first-half 2025-2026: Confirmed excellent growth momentum in home healthcare services: 9.2% / Accelerated growth in the Homecare business, up 6.5% // 2025-2026 targets confirmed
12/02	Bastide Le Confort Médical : Organic growth of 8.2% in first-half 2025-2026: Confirmed excellent growth momentum in home healthcare services: 9.2% / Accelerated growth in the Homecare business, up 6.5% // 2025-2026 targets confirmed